NTS-WBRT in Brain Metastases

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT05013892
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Brain Metastases

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NTS-WBRT (normal tissue sparing whole brain radiation therapy) — RADIATION
    Radiation
  • Memantine — DRUG
    Capsule, taken orally

Study Details

This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT). This research study involves: * NTS-WBRT (normal tissue sparing whole brain radiation therapy) * Memantine standard of care drug

Key Dates

Start date
Feb 8, 2022
Status verified
Apr 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
41 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: NTS-WBRT (normal tissue sparing whole brain radiation therapy) + Memantine
    Participants will be randomly assigned to NTS-WBRT (normal tissue sparing whole brain radiation therapy) administration group and receive: * NTS-WBRT for 5 days (Monday-Friday) for either 2 or 3 weeks. * Memantine per standard of care, 1-2x daily for up to 24 weeks Specific participant administration schedules will be determined by study doctor

Primary Outcome Measure

Change in Patient Reported Quality of Life for NTS-WBRT (normal tissue sparing whole brain radiation therapy) [ Time Frame: 4 Months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General Hospital Cancer CenterBostonMassachusetts02114
Helen A Shih, MD,MS,MPH
[email protected]
617-724-9627
Helen A Shih, MD, MS, MPH (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital Cancer Center· Boston, MA

Related Studies